CAMBRIDGE, Mass. , March 25, 2025 /PRNewswire/ -- Apnimed, Inc., a pharmaceutical company focused on discovery, development, and commercialization of first-in-class oral therapies that address the neuromuscular dysfunction of obstructive sleep apnea (OSA) and other sleep-related breathing diseases, today announced that it will host a virtual investor event on Friday, April 11, 2025 at 12:00 PM ET .
To register, click here. The event will feature leading experts in sleep medicine, Douglas Kirsch , MD, FAAN, FAASM ( Wake Forest University ), and Nathaniel Watson , MD, MSc, FAAN, FAASM ( University of Washington ), who will provide an in-depth analysis of the unmet medical need in OSA and the shifting treatment paradigm. In addition, Apnimed will unveil new analyses exploring the potential impact of pharmacotherapies on the OSA treatment landscape, with a focus on AD109, Apnimed's investigational oral tablet designed to target the neuromuscular root cause of upper airway collapse in people with OSA.
Apnimed's leadership team will also provide an update on its ongoing Phase 3 SynAIRgy and LunAIRo trials, and a preview of Apnimed's go-to-market strategy to unlock the blockbuster potential of AD109. Top-line results from Apnimed's Phase 3 SynAIRgy and LunAIRo clinical trials are expected in the second quarter of 2025 and the third quarter of 2025, respectively. A live question and answer session will follow the presentations and KOL discussion.
About Douglas Kirsch , MD, FAAN, FAAS.
